🇺🇸 FDA
Pipeline program

Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant

2693-CL-1303

Phase 3 small_molecule active

Quick answer

Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant for Moderate to Severe Vasomotor Symptoms (VMS) is a Phase 3 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Astellas Pharma GmbH
Indication
Moderate to Severe Vasomotor Symptoms (VMS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials